Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application
Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...
Aldeyra announces FDA acceptance of resubmitted reproxalap application
Aldeyra (ALDX) announced FDA acceptance of its resubmitted market application for reproxalap and an expansion of its option agreement with AbbVie (ABBV). Read more here.
Business Insider22h
Aldeyra Therapeutics Says FDA Accepts NDA For Reproxalap In Dry Eye Disease
(RTTNews) - Aldeyra Therapeutics, Inc. (ALDX) announced Monday that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular ...